Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.45 |
| ▸ | ERAP2 | Q6P179 | 6/20 | 0.43 |
| ▸ | LNPEP | Q9UIQ6 | 6/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.42 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.40 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.40 |
| ▸ | GHSR | Q92847 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21879807 | 0.88 | CPB2 (0.53) | FOLH1CPB2GSRRNPEPSIRT6 | |
| SCHEMBL28085656 | 0.87 | FOLH1 (0.47) | FOLH1ANPEPCPB2GSRRNPEP | |
| SCHEMBL15148580 | 0.86 | ERAP2 (0.43) | FOLH1ANPEPERAP2LNPEPCPB2 | |
| SCHEMBL5494276 | 0.86 | SIRT6 (0.54) | FOLH1ANPEPERAP2LNPEPERAP1 | |
| SCHEMBL27507131 | 0.86 | FOLH1 (0.46) | FOLH1ANPEPCPB2GSRRNPEP | |
| SCHEMBL2387748 | 0.86 | SIRT6 (0.54) | FOLH1ANPEPERAP2LNPEPERAP1 | |
| Hydrochloric Acid SCHEMBL2122177 | 0.84 | SIRT6 (0.52) | FOLH1ANPEPERAP2LNPEPERAP1 | |
| Hydrochloric Acid SCHEMBL2122175 | 0.84 | SIRT6 (0.52) | FOLH1ANPEPERAP2LNPEPERAP1 | |
| SCHEMBL5333662 | 0.84 | ERAP2 (0.45) | FOLH1ANPEPERAP2LNPEPERAP1 | |
| SCHEMBL5333660 | 0.84 | ERAP2 (0.45) | FOLH1ANPEPERAP2LNPEPERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103293243-B | Detection method and application of carboxy methyl lysine ingredient in food | FUJIAN INSPECTION AND RES INST FOR PRODUCT QUALITY | 2015-05-13 | — | — | CN | claimed |
| US-20240218373-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROINFLAMMATION | AIM IMMUNOTECH INC. (US) | 2024-07-04 | — | — | US | disclosed |
| EP-4388101-A1 | COMPOSITIONS AND METHODS FOR TREATING POST-COVID CONDITIONS OF FATIGUE | AIM ImmunoTech Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| EP-4334451-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROINFLAMMATION | AIM ImmunoTech Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-11813281-B2 | Methods for improving exercise tolerance in myalgic encephalomyelitis patients | AIM IMMUNOTECH INC. (US) | 2023-11-14 | — | — | US | disclosed |
| WO-2023049904-A1 | COMPOSITIONS AND METHODS FOR ENHANCING AND EXPANDING INFECTION INDUCED IMMUNITY | AIM IMMUNOTECH INC. (US) | 2023-03-30 | — | — | WO | disclosed |
| WO-2023023676-A1 | COMPOSITIONS AND METHODS FOR TREATING POST-COVID CONDITIONS OF FATIGUE | AIM IMMUNOTECH INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| US-20220387475-A1 | METHODS AND COMPOSITIONS FOR TREATING ENDOMETRIOSIS | AIM IMMUNOTECH INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220387472-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | AIM IMMUNOTECH INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220389058-A1 | PEPTIDES AND COMPOSITIONS FOR USE IN COSMETICS AND MEDICINE | LIPOTRUE, S.L. (ES) | 2022-12-08 | — | — | US | disclosed |
| WO-2007121922-A2 | BIOMARKERS FOR CHRONIC TRANSPLANT DYSFUNCTION | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| US-7258857-B2 | Rage-related methods for treating inflammation | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2007-08-21 | — | — | US | disclosed |
| US-20060111292-A1 | Compositions for mucosal and oral administration comprising HCG fragments | BIOTEMPT, B.V. (NL) | 2006-05-25 | — | — | US | disclosed |
| EP-1615655-A1 | COMPOSITIONS FOR MUCOSAL AND ORAL ADMINISTRATION COMPRISING HCG FRAGMENTS | Biotempt B.V. (NL) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004093897-A1 | COMPOSITIONS FOR MUCOSAL AND ORAL ADMINISTRATION COMPRISING HCG FRAGMENTS | BIOTEMPT, B.V. (NL) | 2004-11-04 | — | — | WO | disclosed |
| US-20040210042-A1 | Polypeptides relating to signal transfer of advanced glycation end product receptor | MITSUBISHI PHARMA CORPORATION (JP) | 2004-10-21 | — | — | US | disclosed |
| US-20040202645-A1 | Administration of gene-regulatory peptides | BIOTEMPT B.V. (NL) | 2004-10-14 | — | — | US | disclosed |
| EP-1466613-A1 | Compositions for mucosal and oral administration comprising hCG fragments | Biotempt B.V. (NL) | 2004-10-13 | — | — | EP | disclosed |
| EP-1415997-A1 | POLYPEPTIDES RELATING TO SIGNAL TRANSFER OF ADVANCED GLYCATION END PRODUCT RECEPTOR | Mitsubishi Pharma Corporation (JP) | 2004-05-06 | — | — | EP | disclosed |
| US-20020122799-A1 | Methods for treating inflammation | TRANSTECH PHARMA, INC. | 2002-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218373-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROINFLAMMATION | ELAVL1, ELAVL3, SYNCRIP | FOLH1 2235/4885ANPEP 3070/4885ERAP2 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.